Drug Channels
NOVEMBER 15, 2024
Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Click here to learn more about NorstellaLinQ , an integrated data asset that combines claims, labs, and EMR data with forecasting, clinical, payer, and commercial intelligence. Read on for their insights. All rights reserved.
Drug Channels
MAY 21, 2025
The Inflation Reduction Act (IRA) is triggering increases in Medicare beneficiaries spending on their Part B drugs. We find that a growing number of Part B drugs now have inflation-adjusted coinsurance rates that are rising, not falling. Read more 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Channels
MAY 12, 2025
In the video clip below, I explain how PBM compensation models continue to evolve: Traditional profit sources , such as mail dispensing of nonspecialty drugs and retained rebates, have become less significant. Understanding how PBMs generate profits is key to navigating the evolving drug channel landscape.
Drug Channels
FEBRUARY 26, 2025
On March 18, 2025, Drug Channels Institute will release The 2025 Economic Report on U.S. drug pricing, reimbursement, and dispensing system. prescription drug channels. prescription drug channels. Read more 2006-2025 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company.
Drug Channels
JULY 12, 2024
Gavin discusses the three key reasons for duplicate discounts between the 340B Drug Pricing Program and the Medicaid Drug Rebate Program. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. He then explains Oregon’s novel approach to fixing the problem. All rights reserved.
Drug Channels
OCTOBER 18, 2022
The biosimilar boom for provider-administered drugs continues to accelerate. Below, we share our estimates for wholesalers’ gross margins for brand-name, generic, and biosimilar drugs. We then explain the channel dynamics behind biosimilar and generic drugs’ profits. drug distribution. d/b/a Drug Channels Institute.
Drug Channels
JUNE 1, 2023
Vishali discusses the persistent challenges of duplicate discounts between the 340B Drug Pricing Program and the Medicaid Drug Rebate Program. To learn more, sign up now for priority access to Kalderos’ 2023 annual report: Mission Critical: Bringing Drug Discount Stakeholders Together so Patients Win.
Expert insights. Personalized for you.
98 
Let's personalize your content